Association between prophylactic aspirin use and hypertension using data from NHANES 2011-2018

利用2011-2018年NHANES数据探讨预防性服用阿司匹林与高血压之间的关联

阅读:2

Abstract

Aspirin may be necessary for some patients with cardiovascular disease, but previous studies on the use and dosage of aspirin and the association with hypertension have been inadequate. The results of existing studies have been somewhat inconsistent. Our study was designed to assess the association between prophylactic aspirin use and hypertension in U.S. adults. This cross-sectional study analyzed a nationally representative sample of U.S. adults aged 40 and older from the National Health and Nutrition Examination Survey (2011-2018). Aspirin was categorized as no use, low dose (≤ 100 mg), and high dose (> 100 mg). Hypertension was defined as the average of three consecutive blood pressure readings (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg). There were 5297 participants, comprising 52.5% male and 47.4% female. The median age was 64 years (range: 56 to 72) and 3635 individuals were diagnosed with high blood pressure. Among the groups, the incidence of hypertension was 70.2% in the non-aspirin group, 68.3% in the low-dose group, and 68.0% in the high-dose group, with no statistically significant difference observed (p = 0.71). Using a fully adjusted weighted multivariate logistic regression model 4, prophylactic aspirin use was not associated with hypertension [(odds ratio [OR] 1.11; 95% CI (0.89-1.38), (odds ratio [OR] 1.15; 95% CI 0.82-1.61), P = 0.31]. Subgroup analyses, along with sensitivity analyses that excluded patients with diabetes and reclassified aspirin use status, confirmed the findings of the main study. In this nationally representative cohort of U.S. adults, no significant association was found between aspirin use or dosage and the prevalence of hypertension.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。